Side-by-side comparison of AI visibility scores, market position, and capabilities
Newport News VA nuclear shipbuilding (NYSE: HII) $11.1B FY2024 revenue; sole US aircraft carrier builder, Virginia/Columbia-class submarine partner, CVN-79 JFK delivery, AUKUS submarines competing with General Dynamics.
Huntington Ingalls Industries, Inc. (HII) is a Newport News, Virginia-based defense shipbuilding and defense services company — publicly traded on the New York Stock Exchange (NYSE: HII) as an S&P 500 Industrials component — building and maintaining nuclear-powered submarines (Virginia-class attack submarines, Columbia-class ballistic missile submarines) and surface ships (Gerald R. Ford-class nuclear aircraft carriers, America-class amphibious assault ships, Arleigh Burke-class destroyers) through its Newport News Shipbuilding and Ingalls Shipbuilding subsidiaries, and providing defense technology and services through the Mission Technologies segment, through approximately 44,000 employees. HII is the largest military shipbuilder in the United States and the sole builder of US Navy nuclear-powered aircraft carriers (Newport News Shipbuilding — Gerald R. Ford-class carriers, the USS Gerald R. Ford CVN-78 delivered 2017, USS John F. Kennedy CVN-79 under construction) and a partner with General Dynamics Electric Boat for Virginia-class nuclear submarine construction (Newport News builds the stern, propulsion systems, and integration; Electric Boat builds the bow and performs final integration at Groton CT). In fiscal year 2024, HII reported revenues of $11.1 billion (+5% year-over-year), with the Shipbuilding segment generating $8.6 billion and Mission Technologies (defense IT, analytics, C5ISR services) generating $2.5 billion. CEO Chris Kastner has focused on improving shipbuilding performance metrics (on-time delivery, ship quality scores, learning curve efficiency) as the Newport News Shipbuilding facilities executed multiple concurrent complex programs — CVN-79 John F. Kennedy carrier construction, CVN-80 Enterprise carrier material purchasing, Virginia-class Block V submarine sections — amid post-COVID skilled shipwright workforce shortages and supply chain disruptions.
Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.